Pharmacology of the Catecholaminergic System

Wauquier, A.

doi:10.1007/978-3-642-57836-6_4

Cited by 11 publications

(5 citation statements)

References 70 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent studies show increasing evidence that the disturbance of sleep and wakefulness in PD is most intimately related to the disease itself and does not exclusively represent a secondary phenomenon [6], [7]. This primary effect of PD on sleep may be linked to the previously recognized [8], although only recently fully appreciated, role of dopamine (DA) in modulating sleep-wake states [7].…”

Section: Introductionmentioning

confidence: 99%

The Role of the Substantia Nigra Pars Compacta in Regulating Sleep Patterns in Rats

et al. 2007

View full text Add to dashboard Cite

BackgroundAs of late, dopaminergic neurotransmission has been recognized to be involved in the generation of sleep disturbances. Increasing evidence shows that sleep disturbances in Parkinson's disease (PD) patients are mostly related to the disease itself, rather than being a secondary phenomenon. Evidence contained in the literature lends support to the hypothesis that the dopaminergic nigrostriatal pathway is closely involved in the regulation of sleep patterns.Methodology/Principal FindingsTo test this hypothesis we examined the electrophysiological activity along the sleep-wake cycle of rats submitted to a surgically induced lesion of the SNpc by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). We demonstrated that a 50% lesion of the substantia nigra pars compacta (SNpc) suffices to produce disruptions of several parameters in the sleep-wake pattern of rats. A robust and constant decrease in the latency to the onset of slow wave sleep (SWS) was detected throughout the five days of recording in both light [F(22.16) = 72.46, p<0.0001] and dark [F(22.16) = 75.0, p<0.0001] periods. Also found was a pronounced increase in the percentage of sleep efficiency during the first four days of recording [F(21.15) = 21.48, p<0.0001], in comparison to the sham group. Additionally, the reduction in the SNpc dopaminergic neurons provoked an ablation in the percentage of rapid eye movement sleep (REM) during three days of the sleep-wake recording period with a strong correlation (r = 0.91; p<0.0001) between the number of dopaminergic neurons lost and the percentage decrease of REM sleep on the first day of recording. On day 4, the percentage of REM sleep during the light and dark periods was increased, [F(22.16) = 2.46, p<0.0007], a phenomenon consistent with REM rebound.Conclusions/SignificanceWe propose that dopaminergic neurons present in the SNpc possess a fundamental function in the regulation of sleep processes, particularly in promoting REM sleep.

show abstract

Section: Introductionmentioning

confidence: 99%

The Role of the Substantia Nigra Pars Compacta in Regulating Sleep Patterns in Rats

et al. 2007

View full text Add to dashboard Cite

show abstract

“…This primary effect of PD on sleep may be linked to an early recognized (Wauquier, 1995), although only recently fully appreciated, role of dopamine in modulating sleep wake state (Rye and Jankovic, 2002) and a newly described mesothalamic dopaminergic pathway (Freeman et al, 2001).…”

Section: Introductionmentioning

confidence: 99%

The Effect of Cabergoline on Sleep, Periodic Leg Movements in Sleep, and Early Morning Motor Function in Patients with Parkinson's Disease

Högl

Rothdach

Wetter

et al. 2003

Neuropsychopharmacol

View full text Add to dashboard Cite

To investigate the effect of the dopamine D2 and D1 receptor agonist cabergoline on sleep, periodic leg movements (PLMs) in sleep, and early morning motor performance in patients with Parkinson's disease (PD). It was hypothesized that cabergoline had long-lasting beneficial effects on sleep and PLMs in sleep in patients with PD, after a single evening intake. A total of 15 patients with idiopathic PD underwent two nights of polysomnography and motor tests (UPDRS, tapping test) before and after 6-8 weeks of treatment with cabergoline (dosage: 3-6 mg/day). Additionally, patients completed a subjective sleep visual analog scale (VAS) before and during cabergoline treatment. Compared to baseline values, treatment with cabergoline did not change sleep efficiency or the amount of stage 1 and stage 2 sleep. The number of awakenings (22.4 7 10.1 vs 32.5 7 13.3, po0.05) and stage shifts (119 7 42 vs 148 7 46, po0.05) were increased during treatment with cabergoline, and PLMs in sleep were reduced (PLM index 34.9 7 44.9 vs 6.7 7 4.2 per hour, po0.05). Cabergoline significantly improved early morning motor function, and in spite of increased phase shifts and awakenings, patients felt significantly more refreshed in the morning during cabergoline therapy. Cabergoline slightly fragmented sleep, without altering its total amount. The functional significance of this finding is uncertain. The subjective quality of sleep improved, and periodic limb movements in sleep decreased.

show abstract

“…Dopamine deficiency: Apart from the wellknown role of dopamine in motor function, an "active and passive role" in sleep wakefulness regulation has been described and reviewed by Wauquier [41]. Whereas motor function relates to the nigro-striatal dopamine system, the mesocorticolimbic dopamine system has been involved in sleep-wakefulness control.…”

Section: Sleep Disorders In Parkinson's Diseasecontributing Factorsmentioning

confidence: 99%

“…For dopamine agonists a biphasic effect on sleep and wakefulness has been well documented in animal studies. Low-dose apomorphine or pergolide, for instance, induced sleepiness or sleep whereas high doses reduced sleep and increased wakefulness (reviewed in [41]). A biphasic effect on sleep in rats has also been found with the dopamine agonist pramipexole [45].…”

Section: Sleep Disorders In Parkinson's Diseasecontributing Factorsmentioning

confidence: 99%

Sleep and daytime sleepiness in Parkinson's disease

2003

Swiss Arch Neurol Psychiatr

View full text Add to dashboard Cite

Disturbances of sleep and wakefulness in patients with Parkinson's disease (PD) have multiple contributing factors and multiple clinical manifestations.The causes, however, are incompletely understood.Although several of these disturbances have first been described decades ago, awareness for their clinical implications has only increased in recent years, which also prompted new research into the underlying pathomechanisms. The spectrum of sleep and wakefulness disorders in Parkinson's disease comprises sleep fragmentation, microstructural changes, REM-sleep behaviour disorder, periodic limb movements in sleep, respiratory disturbances, autonomic disturbances and daytime sleepiness, which are discussed in detail. Among the contributing factors, dopamine deficiency, motor impairment, the influence of age and comorbid depression, possible genetic influences and the effect of dopaminergic therapy on night sleep and daytime sleepiness are reviewed. Interactions between sleep or sleep deprivation and motor states are discussed (e.g. sleep benefit). One chapter is dedicated to the issue of driving in patients with Parkinson's disease. The final chapter reviews the evaluation of PD patients with sleep disorders and treatment, namely treatment of daytime sleepiness.

show abstract

Pharmacology of the Catecholaminergic System

Cited by 11 publications

References 70 publications

The Role of the Substantia Nigra Pars Compacta in Regulating Sleep Patterns in Rats

The Role of the Substantia Nigra Pars Compacta in Regulating Sleep Patterns in Rats

The Effect of Cabergoline on Sleep, Periodic Leg Movements in Sleep, and Early Morning Motor Function in Patients with Parkinson's Disease

Sleep and daytime sleepiness in Parkinson's disease

Contact Info

Product

Resources

About